Related Experiment Video
Updated: Jun 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Motexafin gadolinium: a novel radiosensitizer for brain tumors
Dave Francis1, Gregory M Richards, Afshin Forouzannia
1University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, K4-B100 Madison, WI 53717, USA.
Abstract:
For a variety of reasons, the management of brain tumors, both primary and metastatic, remains a considerable challenge. As most systemic therapies do not cross the BBB at therapeutic doses, radiation and surgery have played primary roles in the management of these diseases. Despite significant advances in surgical techniques and radiation delivery, outcomes for most adult brain tumors continue to be poor. In an effort to enhance the effects of radiation in the brain, a variety of radiation sensitizers, including motexafin gadolinium, have been investigated. In the following manuscript, we summarize motexafin gadolinium and its role in brain tumors.
Insights
Motexafin gadolinium is being investigated as a radiation sensitizer to improve outcomes for brain tumor patients. This approach aims to enhance radiation therapy effectiveness for primary and metastatic brain tumors.
Area of Science:
- Neuro-oncology
- Radiation Oncology
- Pharmacology
Background:
- Brain tumor management, including primary and metastatic types, presents significant challenges.
- Systemic therapies often fail to cross the blood-brain barrier (BBB) effectively.
- Surgery and radiation are primary treatment modalities, yet patient outcomes remain suboptimal.
Purpose of the Study:
- To review motexafin gadolinium as a potential radiation sensitizer.
- To explore the role of motexafin gadolinium in treating brain tumors.
Main Methods:
- Literature review of motexafin gadolinium.
- Summary of its application in brain tumor management.
Main Results:
- Motexafin gadolinium has been investigated as a radiation sensitizer.
- Its potential to enhance radiation therapy effects in the brain is under study.
Conclusions:
- Motexafin gadolinium shows promise in enhancing radiation therapy for brain tumors.
- Further research is warranted to optimize its use in clinical settings.
